Ipilimumab/pembrolizumabInflammatory polyarthritis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1735卷 / 1期

关键词：

D O I：

10.1007/s40278-019-56779-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：163 / 163

相关论文

共 50 条

[31] Ipilimumab/nivolumabMyocarditis: case report
Reactions Weekly, 2022, 1920 (1) : 268 - 268
[32] Ipilimumab/nivolumabHyperthyroidism: case report
Reactions Weekly, 2022, 1916 (1) : 241 - 241
[33] Ipilimumab/nivolumabMyocarditis: case report
Reactions Weekly, 2022, 1887 (1) : 397 - 397
[34] Ipilimumab/nivolumabMyocarditis: case report
Reactions Weekly, 2019, 1751 (1) : 217 - 217
[35] Ipilimumab/NivolumabPancreatitis: case report
Reactions Weekly, 2024, 2026 (1) : 162 - 162
[36] Ipilimumab/nivolumabMyocarditis : case report
Reactions Weekly, 2023, 1951 (1) : 187 - 187
[37] Ipilimumab/nivolumabHypophysitis: case report
Reactions Weekly, 2021, 1847 (1) : 259 - 259
[38] Ipilimumab/nivolumabHypophysitis: case report
Reactions Weekly, 2023, 1954 (1) : 261 - 261
[39] Ipilimumab/NivolumabHepatotoxicity: case report
Reactions Weekly, 2024, 2038 (1) : 168 - 168
[40] Ipilimumab/nivolumabPancytopenia: case report
Reactions Weekly, 2024, 2023 (1) : 212 - 212

← 1 2 3 4 5 →